Gastroesophageal Reflux Disease

Textbook of Gastroenterology, Fifth Edition

Volumn 1, Issue , 2009, Pages 772-801

  Richter, Joel E ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

barium esophagram inexpensive, readily available noninvasive esophageal test; Esophageal acid clearance; Esophageal manometry; Extraesophageal manifestations; Gastric acid secretion; Gastroesophageal reflux disease (GERD); heartburn classical symptom of GERD; Hypotensive lower esophageal sphincter pressure

Indexed keywords

EID: 70449583555     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303254.ch32     Document Type: Chapter

References (265)

1. Gallup Organization National Survey. Heartburn across America. Princeton, NJ: Gallup Organization, 1988.
2. Locke GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448.
3. Stanghellini V. Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1994; 34: 20.
4. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005; 54: 710.
5. Collen MJ, Abdulian JD, Chen YK. Gastroesophageal disease in the elderly: more severe disease that requires aggressive therapy. Am J Gastroenterol 1995; 90: 1053.
6. Ho KY, Kang JY, Seow A. Prevalence of gastrointestinal symptoms in a multiracial Asian population, with particular reference to reflux-type symptoms. Am J Gastroenterol 1998; 93: 1816.
7. Goh KL, Chang CS, Fock KM, et al. Gastroesophageal reflux disease in Asia. J Gastroenterol Hepatol 2000; 15: 230.
8. Richter JE, Falk GW, Vaezi MF. Helicobacter pylori and gastroesophageal reflux disease: the bug may not be all bad. Am J Gastroenterol 1998; 93: 1800.
9. El-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer disease and reflux disease. Gut 1998; 43: 327.
10. Romero Y, Cameron AJ, Locke GR, et al. Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 1997; 113: 1149.
11. Enck P, Dubois D, Marquis P. Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999; 34: 48.
12. Sloan S, Rademaker AW, Kahrilas PJ. Determinants of gastroesophageal junction incompetence: hiatal hernia, lower esophageal sphincter, or both? Ann Intern Med 1992; 117: 977.
13. Liebermann-Meffert D, Alogower M, Schmid P, Blum A. Muscular equivalent of the lower esophageal sphincter. Gastroenterology 1979; 76: 31.
14. Dodds WJ, Dent J, Hogan WJ, et al. Mechanisms of gastroesophageal reflux in normal human subjects. N Engl J Med 1982; 307: 1547.
15. Dodds WJ, Dent J, Hogan W, Arndorfer R. Effect of atropine on esophageal motor function in humans. Am J Physiol 1981; 241: G290.
16. Marchand P. The anatomy of esophageal hiatus of the diaphragm and the pathogenesis of hiatus herniation. Thorac Surg 1959; 37: 81.
17. Mittal RK, Balaban DH. The esophagogastric junction. N Engl J Med 1997; 336: 924.
18. Marshall JB, Berger WL. End-expiratory pressure best approximates intrinsic lower esophageal sphincter pressure. Dig Dis Sci 1990; 35: 267.
19. Mittal RK, Rochester DF, McCallum RW. Electrical and mechanical activity in the human lower esophageal sphincter during diaphragmatic contraction. J Clin Invest 1988; 81: 1182.
20. Thor KB, Hill RD, Mercer DD, Kozarek RD. Reappraisal of the flap valve mechanism in the gastroesophageal junction: a study of a new valvuloplasty procedure in cadavers. Acta Chir Scand 1987; 153: 25.
21. Holloway RH, Penagini R, Ireland AC. Criteria for objective definition of transient lower esophageal sphincter relaxation. Am J Physiol 1995; 268: G128.
22. Dent J, Holloway RH, Toouli J, Dodds WJ. Mechanisms of lower esophageal sphincter incompetence in patients with symptomatic gastroesophageal reflux. Gut 1988; 29: 1020.
23. Bredenoord AJ, Weusten BLAM, Timmer R, Smout AJPM. Intermittent spatial separation of diaphragm and lower esophageal sphincter favors acidic and weakly acidic reflux. Gastroenterology 2006; 125: 1018.
24. Mittal RK, McCallum RW. Characteristics of transient lower esophageal sphincter relaxation in humans. Am J Physiol 1987; 252: G636.
25. Schoem MN, Tippett MD, Akkermans LM, et al. Mechanisms of gastroesophageal reflux in ambulant healthy human subjects. Gastroenterology 1995; 108: 83.
26. Mittal RK, Holloway RH, Penagini R, et al. Transient lower esophageal sphincter relaxation. Gastroenterology 1995; 109: 601.
27. Holloway RH, Kocyan P, Dent J. Provocation of transient lower esophageal sphincter relaxation by meals in patients with symptomatic gastroesophageal reflux. Dig Dis Sci 1991; 36: 1034.
28. Holloway RH. The anti-reflux barrier and mechanisms of gastrooesophageal reflux. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 681.
29. Holloway R, Wyman J, Dent J. Failure of transient lower oesophageal sphincter relaxation in response to gastric distention in patients with achalasia: evidence for neural medication of transient lower oesophageal sphincter relaxation. Gut 1989; 30: 762.
30. Dent J, Dodds WJ, Friedman RH, et al. Mechanism of gastroesophageal reflux in recumbent asymptomatic subjects. J Clin Invest 1980; 65: 256.
31. Mittal RK, Lange RC, McCallum RW. Identification and mechanism of delayed esophageal acid clearance in subjects with hiatus hernia. Gastroenterology 1987; 92: 130.
32. Salapatek AMF, Diamant NE. Assessment of neural inhibition of the lower esophageal sphincter in cats with esophagitis. Gastroenterology 1993; 104: 810.
33. Singh P, Adamopoulos A, Taylor RH, Colin-James DG. Oesophageal motor function before and after healing of oesophagitis. Gut 1992; 33: 1590.
34. Sontag SJ, Schnell TG, Miller TQ, et al. The importance of hiatal hernia in reflux esophagitis compared with lower esophageal sphincter pressure or smoking. J Clin Gastroenterol 1991; 13: 628.
35. Kahrilas PJ, Lin S, Chen J, Manka M. The effect of hiatus hernia on gastro-esophageal junction pressure. Gut 1999; 44: 476.
36. Sloan S, Kahrilas PJ. Impairment of esophageal emptying with hiatal hernia. Gastroenterology 1991; 100: 596.
37. Kahrilas PJ, Shi G, Manka M, Joehl RJ. Increased frequency of transient lower esophageal sphincter relaxation induced by gastric distension in reflux patients with hiatal hernia. Gastroenterology 2000; 118: 688.
38. Paterson WG, Kolyn DM. Esophageal shortening induced by short-term intraluminal acid perfusion: a cause for hiatus hernia? Gastroenterology 1994; 107: 1736.
39. Wilson LJ, Ma W, Hirschowitz BI. Association of obesity with hiatus hernia and esophagitis. Am J Gastroenterol 1999; 94: 262.
40. Smith AB, Dickerman RD, McGuire CS, et al. Pressure overload induced sliding hiatal hernia in power athletes. J Clin Gastroenterol 1999; 28: 352.
41. Orr WC, Robinson MG, Johnson LF. Acid clearance during sleep in the pathogenesis of reflux esophagitis. Dig Dis Sci 1981; 26: 423.
42. Helm JF, Dodds WJ, Pek LR, et al. Effect of esophageal emptying and saliva on clearance of acid from the esophagus. N Engl J Med 1984; 310: 284.
43. Kahrilas PJ, Dodds WJ, Hogan WJ, et al. Esophageal peristaltic dysfunction in peptic esophagitis. Gastroenterology 1986; 91: 897.
44. Johnson LF, DeMeester TR. Elevation of the head of the bed, bethanechol and antacid foam tablets on gastroesophageal reflux. Dig Dis Sci 1976; 26: 673.
45. Helm JF, Dodds WJ, Hogan WJ, et al. Acid neutralizing capacity of human saliva. Gastroenterology 1987; 83: 69.
46. Korstein MA, Rosman AS, Fishbein S, et al. Chronic xerostomia increases esophageal acid exposure and is associated with esophageal injury. Am J Med 1991; 90: 701.
47. Kahrilas PJ, Gupta RR. The effect of cigarette smoking on salivation and esophageal acid clearance. J Lab Clin Med 1989; 114: 431.
48. Helm JF, Dodds WJ, Ricdel DR, et al. Determinants of esophageal acid clearance in normal subjects. Gastroenterology 1983; 86: 607.
49. Meyers RL, Orlando RC. In vivo bicarbonate secretion by human esophagus. Gastroenterology 1992; 103: 1174.
50. Brown CM, Snowdon CF, Slee B, et al. Effect of topical oesophageal acidification on human salivary and oesophageal alkali secretion. Gut 1995; 36: 649.
51. Orlando RC. Esophageal epithelial defenses against acid injury. Am J Gastroenterol 1994; 89: 349.
52. Quigley EMM, Turnberg LA. pH of the microclimate lining human gastric and duodenal mucosa in vivo: studies in control subjects and in duodenal ulcer patients. Gastroenterology 1987; 92: 1876.
53. Orlando RC, Lacey ER, Tobey NA, Cowart K. Barriers to paracellular permeability in rabbit esophageal epithelium. Gastroenterology 1992; 102: 910.
54. Tobey NA, Reddy SP, Khalbuss WE, et al. Na+ dependent and independent C1-/HCO3 -exchanges in cultured rabbit esophageal epithelial cells. Gastroenterology 1993; 104: 185.
55. Layden TJ, Schmidt L, Agone L, et al. Rabbit esophageal cell cytoplasmic pH regulation: role of Na+-H+ antiport and Na+-dependent HCO3 -transport systems. Am J Physiol 1992; 263: G407.
56. Hollwarth ME, Smith M, Kvietys PR, et al. Esophageal blood flow in the cat: normal distribution and effects of acid perfusion. Gastroenterology 1986; 90: 622.
57. DeBacker A, Haentigens P, Willems G. Hydrochloric acid: a trigger of cell proliferation in the esophagus. Dig Dis Sci 1985; 30: 884.
58. Orlando RC, Bryson JC, Powell DW. Mechanisms of H+ injury in rabbit esophageal epithelium. Am J Physiol 1984; 246: G718.
59. Stein HJ, Barlow AP, DeMeester TR, Hinder RA. Complications of gastroesophageal reflux disease. Ann Surg 1992; 216: 35.
60. Gillen P, Keeling P, Byrne PJ, Hennessy TPJ. Barrett's esophagus: pH profile. Br J Surg 1987; 74: 774.
61. Collen MJ, Lewis JH, Benjamin SB. Gastric acid hypersecretion in refractory GERD. Gastroenterology 1990; 98: 654.
62. Hirschowitz BI. A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology 1991; 101: 1149.
63. Vicari J, Peek RM, Falk GW, et al. The seroprevalance of cagApositive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998; 115: 50.
64. Loffeld RJLF, Werdmuller BFM, Kusta JG, et al. Colonization with cagA-positive H. pylori strains is inversely associated with reflux esophagitis and Barrett's esophagus. Digestion 2000; 62: 95.
65. Labenz J, Malfertheiner P. H. pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor. Gut 1997; 41: 277.
66. Labenz J, Blum AL, Bayerdorffer E, et al. Curing H. pylori infection in duodenal ulcer patients may provoke reflux esophagitis. Gastroenterology 1997; 112: 1442.
67. Fallone CA, Barkun AN, Friedman G, et al. Is Helicobacter pylori eradication associated with gastroesophageal reflux disease? Am J Gastroenterol 2000; 95: 914.
68. Lillemoe KD, Johnson LF, Harmon JW. Alkaline esophagitis: a comparison of the ability of components of the gastroduodenal contents to injure the rabbit esophagus. Gastroenterology 1983; 85: 621.
69. Attwood SEA, DeMeester TR, Bremner CG, et al. Alkaline gastroesophageal reflux: implications in the development of complications in Barrett's columnar-lined esophagus. Surgery 1989; 106: 764.
70. Pellegrini CA, DeMeester TR, Wernly JA, et al. Alkaline gastroesophageal reflux. Am J Surg 1978; 75: 177.
71. Bechi P, Pucciani F, Baldini F, et al. Long-term ambulatory enterogastric reflux monitoring: validation of a new fiberoptic technique. Dig Dis Sci 1993; 38: 1297.
72. Sifrim D, Holloway R, Silny J, et al. Acid, non-acid and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordings. Gastroenterology 2001; 120: 1588.
73. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996; 111: 1192.
74. Champion G, Richter JE, Vaezi MF, et al. Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology 1994; 107: 747.
75. Schweitzer EJ, Bass B, Batzri S, Harmon J. Bile acid accumulation by rabbit esophageal mucosa. Dig Dis Sci 1986; 31: 1105.
76. McCallum RW, Berkowitz DM, Lerner E. Gastric emptying in patients with gastroesophageal reflux. Gastroenterology 1981; 80: 285.
77. Shay SS, Eggli D, McDonald C, Johnson LF. Gastric emptying of solid food in patients with gastroesophageal reflux. Gastroenterology 1987; 92: 459.
78. Schwizer W, Hinder RA, DeMeester TR. Does delayed gastric emptying contribute to gastroesophageal reflux? Am J Surg 1989; 157: 74.
79. Van Thiel DM, Gravaler JS, Josh SN, et al. Heartburn of pregnancy. Gastroenterology 1977; 72: 666.
80. Zamost BJ, Hirschberg J, Ippoliti AF, et al. Esophagitis in scleroderma: prevalence and risk factors. Gastroenterology 1987; 92: 421.
81. Miller LS, Vinayek R, Frucht H, et al. Reflux esophagitis in patients with the Zollinger-Ellison syndrome. Gastroenterology 1990; 98: 341.
82. Vaezi MF, Richter JE. Current therapies for achalasia: comparison and efficacy. J Clin Gastroenterol 1998; 27: 21.
83. Nagler R, Spiro HM. Persistent gastroesophageal reflux induced during prolonged gastric intubation. N Engl J Med 1963; 269: 495.
84. Carlsson R, Dent J, Bolling-Sternevold E, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998; 33: 1023.
85. Klauser AG, Schindlebeck NE, Muller-Lissner SA. Symptoms of gastro-oesophageal reflux disease. Lancet 1990; 335: 205.
86. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management: the Genval report. Gut 1999; 44(Suppl 2): S1.
87. Powell DW. Barrier function of epithelial. Am J Physiol 1981; 241: G275.
88. Jacob P, Kahrilas PJ, Vanagunos A. Peristaltic dysfunction associated with non-obstructive dysphagia in reflux disease. Dig Dis Sci 1990; 35: 939.
89. Brzana RJ, Koch KL. Gastroesophageal reflux disease presenting with intractable nausea. Ann Intern Med 1997; 126: 704.
90. Johnson DA, Winters C, Spurling TJ, et al. Esophageal acid sensitivity in Barrett's esophagus. J Clin Gastroenterol 1987; 9: 23.
91. Richter JE. Extraesophageal presentations of gastroesophageal reflux disease. Am J Gastroenterol 2000; 25(Suppl): S1.
92. Schofied PM, Bennett DH, Whorewell PJ, et al. Exertional gastroesophageal reflux: a mechanism for symptoms in patients with angina pectoris and normal coronary angiograms. Br Med J 1987; 294: 1459.
93. Hewson EG, Sinclair JW, Dalton CB, et al. Twenty-four hour esophageal pH monitoring: the most useful test for evaluating non-cardiac chest pain. Am J Med 1991; 90: 576.
94. Richter JE. Approach to the patient with non-cardiac chest pain. In: Yamada T (ed.). Textbook of Gastroenterology, 2nd edn. Philadelphia, PA: JB Lippincott, 1995: 648.
95. Singh S, Richter JE, Hewson EG, et al. The contribution of gastroesophageal reflux to chest pain in patients with coronary artery disease. Ann Intern Med 1992; 117: 824.
96. Osler WB. The Principles of Internal Medicine. New York: Appleton, 1892.
97. Sontag SJ, O'Connell S, Khandelwal S, et al. Most asthmatics have gastroesophageal reflux with or without bronchodilator therapy. Gastroenterology 1990; 99: 613.
98. Harding SM, Sontag SJ. Asthma and gastroesophageal reflux. Am J Gastroenterol 2000; 95(Suppl): S23.
99. Irwin RS, Curley FJ, French CL. Difficult-to-control asthma: contributing factors and outcome of a systematic protocol. Chest 1993; 103: 1662.
100. Tuchman DN, Boyle JT, Pack AI, et al. Comparison of airway responses following tracheal or esophageal acidification in the cat. Gastroenterology 1984; 87: 872.
101. Schan CA, Harding SM, Haile JM, et al. Gastroesophageal reflux-induced bronchoconstriction: an intraesophageal acid infusion study using state-of-the-art technology. Chest 1994; 105: 731.
102. Jack CIA, Calverley PMA, Donnelly RJ, et al. Simultaneous tracheal and oesophageal pH measurements in asthmatics patients with gastro-oesophageal reflux. Thorax 1995; 50: 201.
103. Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease: a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope 1978; 88: 339.
104. Wong RKH, Hanson DG, Waring PJ, Shaw G. ENT manifestations of gastroesophageal reflux. Am J Gastroenterol 2000; 95(Suppl): S15.
105. Irwin RS, Richter JE. Gastroesophageal reflux and cough. Am J Gastroenterol 2000; 95(Suppl): S39.
106. Lazarchik DA, Filler SJ. Dental erosion: predominant oral lesion in gastroesophageal reflux disease. Am J Gastroenterol 2000; 95(Suppl): S33.
107. Jacob P, Kahrilas PH, Herzon G. Proximal esophageal pH: manometry in patients with "reflux laryngitis". Gastroenterology 1991; 100: 305.
108. Schindlebeck NE, Klauser AG, Voderholzer WA, Mueller-Lissner S. Empiric therapy for gastroesophageal reflux disease. Arch Intern Med 1995; 155: 1808.
109. Fass R, Ofman JJ, Granelk I, et al. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med 1999; 159: 2161.
110. Fass R, Fennerty MB, Ofman JJ. The clinical and economic value of a short course of omeprazole in patients with non-cardiac chest pain. Gastroenterology 1998; 115: 42.
111. Ours TM, Kavuru MS, Schilz R, Richter JE. A prospective evaluation of esophageal testing and a double blind, randomized study of omeprazole in a diagnostic and therapeutic algorithm for chronic cough. Am J Gastroenterol 1999; 94: 3131.
112. Richter JE. Severe reflux esophagitis. Gastrointest Endosc Clin North Am 1994; 4: 677.
113. Johnson LF, DeMeester, Haggitt RC. Endoscopic signs of gastroesophageal reflux objectively evaluated. Gastrointest Endosc 1976; 22: 151.
114. Ollyo JB, Lang F, Fontolliet C, Monnier P. Savary-Miller's new endoscopic grading of reflux-oesophagitis: a simple, reproducible, logical, complete and useful classification. Gastroenterology 1990; 98: A100.
115. Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report of observer agreement. Gastroenterology 1996; 111: 85.
116. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 903.
117. Funch-Jensen P, Kock K, Christensen LA, et al. Microscopic appearance of the esophageal mucosa in a consecutive series of patients submitted to endoscopy: correlation with gastroesophageal reflux symptoms and microscopic findings. Scand J Gastroenterol 1986; 21: 65.
118. Riddell RH. The biopsy diagnosis of gastroesophageal reflux disease, "carditis," and Barrett's esophagus. Am J Surg Pathol 1996; 20: 31.
119. Dent J. Microscopic esophageal mucosal injury in non-erosive reflux disease. Clin Gastroenterol Hepatol 2007; 5: 4.
120. Tunmmala V, Barwick KW, Sontag S, et al. The significance of intraepithelial eosinophils in the histological diagnosis of gastroesophageal reflux disease. Am J Clin Pathol 1987; 87: 43.
121. Winters HS, Madara JL, Stafford RJ, et al. Intraepithelial eosinophils: a new diagnostic criterion for reflux esophagitis. Gastroenterology 1982; 83: 818.
122. DeMeester TR, Johnson LF, Joseph GJ, et al. Pattern of gastroesophageal reflux in health and disease. Ann Surg 1976; 184: 459.
123. Hirano I, Richter JE. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol 2007; 102: 668.
124. Taghavi SA, Ghasedi M, Saberi-Firoozi M, et al. Symptom association probability and symptom sensitivity index: preferable but still suboptimal predictors of response of high dose omeprazole. Gut 2005; 54: 1067.
125. Shaker R, Milbrath M, Ren J, et al. Esophagopharyngeal distribution of refluxed gastric acid in patients with reflux laryngitis. Gastroenterology 1995; 109: 1575.
126. Richter JE. Ear nose and throat and respiratory manifestations of GERD; an increasing conundrum. Eur J Gastroenterol Hepatol 2004; 16: 1.
127. Pandolfino JE, Richter JE, Ours T, et al. Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol 2003; 98: 740.
128. Sifrim D, Holloway R, Silny J, et al. Acid, non-acid and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour impedance recordings. Gastroenterology 2001; 120: 1599.
129. Ott DJ, Kelley TF, Chen MYM, et al. Use of a marshmallow bolus for evaluating lower esophageal mucosal rings. Am J Gastroenterol 1991; 86: 817.
130. Baker ME, Eistein DM, Hertz BR, et al. Integrating the barium esophagram before and after anti-reflux surgery. Radiology 2007; 243: 329.
131. Thompson JK, Koehler RE, Richter JE. Detection of gastroesophageal reflux: value of the barium studies compared with 24-hour pH monitoring. AJR Am J Roentgenol 1994; 162: 621.
132. Johnston BT, Troshinsky MB, Castell JA, Castell DO. Comparison of barium radiology with esophageal pH monitoring in the diagnosis of gastroesophageal reflux disease. Am J Gastroenterol 1996; 91: 1181.
133. Waring JP, Hunter JG, Oddsdottir M. The preoperative evaluation of patients considered for laparoscopic antireflux surgery. Am J Gastroenterol 1995; 90: 35.
134. Leite LP, Johnston BT, Barrett J, et al. Ineffective esophageal motility: the primary finding in patients with non-specific esophageal motility disorder. Dig Dis Sci 1997; 42: 1853.
135. Oleynikov D, Eubanks TR, Oelschlager BK, Pellegrini CA. Total fundoplication is the operation of choice for patients with gastroesophageal reflux and defective peristalsis. Surg Endosc 2002; 16: 909.
136. Tutian R, Castell DO. Clarification of the esophageal function defect in patients with manometric ineffective esophageal motility: studies using combined impedance-manometry. Gastroenterology 2004; 2: 230.
137. Pace F, Santalucia F, Bianchi-Porro G. Natural history of gastroesophageal reflux disease without esophagitis. Gut 1991; 32: 845.
138. Labenz J, Nocon M, Lind T, et al. Prospective follow-up from the ProGERD study suggests that GERD is not a categorical disease. Am J Gastroenterol 2006; 101: 2457.
139. Winters C, Spurling TJ, Chokanian SJ, et al. Barrett's esophagus: a prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987; 92: 118.
140. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagi-tis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 974.
141. Jones RH, Hungin ADS, Phillips J, et al. Gastroesophageal reflux disease in primary care in Europe: clinical presentation and endoscopic findings. Eur J Gen Pract 1995; 1: 149.
142. Robinson M, Earnest D, Rodriguez-Stanley S, et al. Heartburn requiring frequent antacid use may indicate significant illness. Arch Intern Med 1998; 156: 2373.
143. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease: current concepts and dilemmas. Am J Gastroenterol 2001; 96: 303.
144. Caviglia R, Ribolsi M, Maggiano N, et al. Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological esophageal acid exposure. Am J Gastroenterol 2005; 100: 543.
145. Feldman M, Barnett C. Relationship between the acidity and osmolality of popular beverages and reported postprandial heartburn. Gastroenterology 195; 108: 125.
146. Trimble KC, Douglas S, Pryde A, Heading RC. Clinical characteristics and natural history of symptomatic but not excess gastroesophageal reflux. Dig Dis Sci 1995; 40: 1098.
147. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 903.
148. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106.
149. Isolauri J, Luostarinen M, Isolauri E, et al. Natural history of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol 1997; 92: 37.
150. Brossard E, Monnier JB, Ollyo JB, et al. Serious complications -stenosis, ulcer and Barrett's epithelium -develop in 21.6% of adults with erosive reflux esophagitis. Gastroenterology 1992; 100: A36.
151. Spechler SJ. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. N Engl J Med 1992; 326: 786.
152. Rejeb MB, Bouché O, Zeitoun P. Study of 47 consecutive patients with peptic esophageal stricture compared with 3880 cases of reflux esophagitis. Dig Dis Sci 1992; 37: 7338.
153. DaCosta N, Guillaume C, Merle C, et al. Bleeding reflux esophagitis: a prospective 1-year study in a university hospital. Am J Gastroenterol 2001; 96: 47.
154. Richter JE. Peptic strictures of the esophagus. Gastroenterol Clin North Am 1999; 28: 875.
155. El-Serag HB, Sonnenberg A. Association of esophagitis and esophageal strictures with diseases treated with non-steroidal anti-inflammatory drugs. Am J Gastroenterol 1997; 92: 52.
156. Sgouros SN, Vlachogiannakos J, Karamanolis G, et al. Long-term acid suppression therapy may prevent the relapse of lower esophageal (Schatzki's) rings: a prospective, randomized, placebo-controlled study. Am J Gastroenterol 2005; 100: 1924.
157. Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago workshop. Gastroenterology 2004; 127: 310.
158. Iascone C, DeMeester TR, Little AG, Skinner DB. Barrett's esophagus: functional assessment, proposed pathogenesis, and surgical therapy. Arch Surg 1983; 118: 543.
159. Lieberman DA, Oeklke M, Helfand M, GORGE Consortium. Risk factors for Barrett's esophagus in community-based practice. Am J Gastroenterol 1997; 92: 1293.
160. Bremner CG, Lynch VP, Ellis FH. Barrett's esophagus: congenital or acquired. An experimental study of esophageal mucosal regeneration in the dog. Surgery 1970; 68: 209.
161. Boch JA, Shields HM, Antonioli DA. Distribution of cytokeratin markers in Barrett's specialized columnar epithelium. Gastroenterology 1997; 112: 760.
162. Cameron A, Zinsmeister A, Ballard D, Carney JA. Prevalence of columnar-lined (Barrett's) esophagus: comparison of population-based clinical and autopsy findings. Gastroenterology 1990; 99: 918.
163. Cameron A, Lomboy C. Barrett's esophagus: age, prevalence and extent of columnar epithelium. Gastroenterology 1992; 103: 1241.
164. Hassel E. Barrett's esophagus: new definitions and approaches in children. J Pediatr Gastroenterol Nutr 1993; 16: 345.
165. Jochem VJ, Fuerst PA, Fromkes JJ. Familial Barrett's esophagus association with adenocarcinoma. Gastroenterology 1992; 102: 1400.
166. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 2006; 131: 1392.
167. Paull A, Trier JS, Dalton MD, et al. The histologic spectrum of Barrett's esophagus. N Engl J Med 1976; 295: 476.
168. Sharma P. Recent advances in Barrett's esophagus: short-segment Barrett's esophagus and cardia intestinal metaplasia. Semin Gastrointest Dis 1999; 10: 93.
169. Oberg S, Peter JH, DeMeester TR, et al. Inflammation and specialized intestinal metaplasia of cardia mucosa is a manifestation of gastroesophageal reflux disease. Ann Surg 1997; 226: 522.
170. Goldblum JR, Vicari JJ, Falk GW, et al. Inflammation and intestinal metaplasia of the gastric cardia: the role of gastroesophageal reflux and H. pylori infection. Gastroenterology 1998; 114: 633.
171. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985; 313: 857.
172. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study in 170 patients followed 4.8 years. Am J Gastroenterol 1997; 92: 212.
173. Anderson LA, Murray LJ, Murphy SJ, et al. Mortality in Barrett's esophagus: results from a population based study. Gut 2003; 52: 1081.
174. DeVesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049.
175. Dulai GS, Guha S, Kahn KL, et al. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systemic review. Gastroenterology 2002; 122: 26.
176. Kaltenback T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence based medicine approach. Arch Intern Med 2006; 166: 965.
177. Meining A, Classen M. The role of diet and lifestyle measures in the pathogenesis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95: 2692.
178. Harvey RF, Gordon PC, Hadley N, et al. Effects of sleeping with the bed-head raised and of ranitidine in patients with severe peptic esophagitis. Lancet 1987; 2: 1200.
179. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk of gastroesophageal reflux disease and its complications. Ann Intern Med 2005; 143: 199.
180. Dennish GW, Castell DO. Inhibiting effect of smoking on the lower esophageal sphincter. N Engl J Med 1971; 284: 1136.
181. Kaufman SE, Kaye MD. Induction of gastroesophageal reflux by alcohol. Gut 1978; 19: 336.
182. Weberg R, Berstad A. Symptomatic effect of a low-dose antacid regimen in reflux oesophagitis. Scand J Gastroenterol 1989; 24: 401.
183. Buts JP, Barudi C, Otte JB. Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24h continuous pH monitoring in infants and children. Eur J Pediatr 1987; 146: 156.
184. Behar J, Sheahan DG, Biancani P, et al. Medical and surgical management of reflux esophagitis: a 38-month report on a prospective clinical trial. N Engl J Med 1975; 293: 263.
185. Gonzalez ER, Grillo JA. Over-the-counter histamine2-blocker therapy. Ann Pharmacother 1994; 28: 392.
186. Fendrick AM, Shaw M, Schachtel B, et al. Self-selection and use patterns of over-the-counter omeprazole for frequent heartburn. Clin Gastroenterol Hepatol 2004; 2: 17.
187. Ramirez B, Richter JE. Promotility drugs in the treatment of gastroesophageal reflux disease. Aliment Pharmacol Ther 1993; 7: 5.
188. Dilawari JB, Misiewcz JJ. Action of metoclopramide on the GE junction in man. Gut 1973; 14: 380.
189. Wysowski DK, Corken A, Gallo-Torres H, et al. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory action. Am J Gastroenterol 2001; 96: 1698.
190. Lipsy RJ, Fennerty B, Fagan TC. Clinical review of histamine-2 receptor antagonists. Arch Intern Med 1990; 150: 745.
191. Sontag SJ. Gastroesophageal reflux disease. In: Brandt LJ (ed.). Clinical Practice of Gastroenterology. Philadelphia, PA: Churchill Livingstone, 1999: 21.
192. Chiba N, Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798.
193. Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93: 763.
194. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115: 1335.
195. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long term effect of H2 RA therapy or nocturnal gastric acid breakthrough. Gastroenterology 2002; 112: 625.
196. Wilder-Smith CH, Merki HS. Tolerance during dosing with H2receptor antagonists: an overview. Scand J Gastroenterol Suppl 1992; 27: 14.
197. Klinkenberg-Knol EC, Festen HPM, Meuwissen SGM. Pharmacological management of gastro-oesophageal reflux disease. Drugs 1995; 49: 697.
198. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000; 118(Suppl): 9.
199. Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med 1999; 159: 649.
200. Carlson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1998; 10: 119.
201. Sontag SJ, Hirschowitz BH, Holt S, et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the US multi-center study. Gastroenterology 1992; 102: 109.
202. Castell DO, Richter JE, Robinson M, et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. Am J Gastroenterol 1996; 91: 1749.
203. Cloud ML, Enas N, Humphries TJ, et al. Rabeprazole in treatment of acid peptic diseases. Dig Dis Sci 1998; 43: 993.
204. Richter JE, Bochenek W. Pantoprazole US GERD Study Group. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Am J Gastroenterol 2000; 95: 3071.
205. van Pinxteren B, Numan ME, Bonis PA, Lau J. Short-term treatment with proton-pump inhibitors, H2RAs and prokinetic for gastroesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2004; 3: CD002095.
206. Bianchi Porro G, Pace F, Peracchia A, et al. Short-term management of refractory reflux esophagitis with different doses of omeprazole or ranitidine. J Clin Gastroenterol 1992; 15: 192.
207. Gralnek IM, Dulai GS, Fennerty MB, Spiegel BNR. Esompeprazole vs other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol 2006; 4: 1452.
208. Garnett WR. Consideration for long-term use of proton pump inhibitors. Am J Health Syst Pharm 198; 55: 2269.
209. Toussaint J, Gossuin A, Deruyttere M, et al. Healing and prevention of relapse of reflux esophagitis by cisapride. Gut 1991; 35: 590.
210. Robinson M, Lanza F, Avener D, Haber M. Effective maintenance treatment of reflux esophagitis with low-dose omeprazole. Ann Intern Med 1996; 124: 859.
211. Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux esophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2004; 3: CD003245.
212. Dent J, Yeomano ND, Mackinnon M, et al. Omeprazole v. ranitidine for prevention of relapse in reflux oesophagitis: a controlled double blind trial of their efficacy and safety. Gut 1994; 35: 590.
213. Klinkenberg-Knol EC, Feston HPM, Janssen JBM, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161.
214. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661.
215. Howden CW. Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol 2000; 30: 29.
216. Freston JW. Omeprazole, hypergastrinemia and gastric carcinoid tumors. Ann Intern Med 1994; 121: 232.
217. Kuipers E, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018.
218. Food and Drug Administration (FDA). Proton Pump Inhibitors Relabeling for Cancer Risk not Warranted. Washington, DC: FDA, 1996.
219. Richter JE. Gastroesophageal reflux disease in the older patient: presentation, treatment and complications. Am J Gastroenterol 2000; 95: 368.
220. Zimmerman A, Walters JK, Katona B, et al. Alternative methods of proton pump inhibitor administration. Consult Pharm 1997; 9: 990.
221. Richter JE. Review article: the management of heartburn during pregnancy. Aliment Pharmacol Ther 2005; 23: 749.
222. Ranchet G, Gangemi O, Petrone M. Sucralfate in the treatment of gravid pyrosis. G Ital Ostet Ginecol 1990; 12: 1.
223. Larson JP, Patatanian E, Miner PB, et al. Double-blind, placebo controlled study of ranitidine for gastroesophageal reflux disease symptoms during pregnancy. Obstet Gynecol 1997; 90: 83.
224. Cremmini F, Wise J, Moayyedi P, Talley N. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a meta-analysis. Am J Gastroenterol 2005; 100: 1226.
225. Dakkak M, Hoare RC, Maslin SC, et al. Oesophagitis is as important as oesophageal stricture diameter in determining dysphagia. Gut 1993; 34: 152.
226. Riley SA, Attwood SEA. Guidelines on the use of esophageal dilation in clinical practice. Gut 2004; 55: 1.
227. Marks RD, Richter JE, Rizzo J, et al. Omeprazole vs H2RAs in treating patients with peptic stricture and esophagitis. Gastroenterology 1994; 106: 907.
228. Triadafilopoulous G. Proton pump inhibitors for Barrett's esophagus. Gut 2000; 46: 144.
229. Ouator-Lascar R, Fitzgerald RC, Triadafilopoulous G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999; 17: 327.
230. El-Serag HB, Aguirre T, Davis S, et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004; 99: 1877.
231. Barr H, Stone N, Rembacken B. Endoscopic therapy for Barrett's esophagus. Gut 2005; 54: 875.
232. Van Laethem JL, Peny MO, Salman I, et al. Intramucosal adenocarcinoma arising under squamous re-epithelialization of Barrett's oesophagus. Gut 2000; 46: 574.
233. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc 1999; 49: 1.
234. Reid BJ, Weinstein WM, Lewin KJ, et al. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. Gastroenterology 1988; 94: 81.
235. Geisinger KR. Endoscopic biopsies and cytologic brushings of the esophagus are diagnostically complementary. Am J Clin Pathol 1995; 103: 295.
236. Van Leishout EM, Jansen JB, Peters WH. Biomarkers in Barrett's esophagus. Int J Oncol 1998; 13: 855.
237. Reid BJ, Haggitt RC, Rubin CE, et al. Barrett's esophagus: correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology 1987; 93: 1.
238. Van Sandick JW, van Laschott JJB, Kuiken BW, et al. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998; 43: 216.
239. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008; 103: 788.
240. Schnell T, Sontag SJ, Chejfee G, et al. Long-term nonsurgical management of Barrett's esophagus with high grade dysplasia. Gastroenterology 2001; 120: 1607.
241. Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low-and high-risk patient subsets. Am J Gastroenterol 2000; 95: 1669.
242. Weston A, Sharma P, Mathur S, et al. Risk stratification of Barrett's esophagus: an updated prospective multivariate analysis. Am J Gastroenterol 2004; 99: 1657.
243. Inadomi JM, Sampliner R, Lagergren JE, et al. Screening and surveillance for Barrett's esophagus in high-risk groups: a cost-utilization analysis. Ann Intern Med 2003; 138: 176.
244. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002; 123: 461.
245. Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003; 125: 1670.
246. Corley DA, Kerlikowski K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systemic review and meta-analysis. Gastroenterology 2003; 124: 246.
247. Morris CD, Armstrong GR, Bigley G, et al. Cyclooxgenase-2-expression in Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001; 96: 990.
248. Ireland AC, Holloway RH, Toouli J, Dent J. Mechanisms underlying the anti-reflux action of fundoplication. Gut 1993; 34: 303.
249. Rice TW. Why antireflux surgery fails. Dig Dis 2000; 18: 43.
250. DeMeester TR, Bonavina L, Albertucci M. Nissen fundoplication for gastroesophageal reflux disease: evaluation of primary repair in 100 consecutive patients. Ann Surg 1986; 204: 9.
251. Horvath KD, Jobe BA, Herron DM, Swanstrom LL. Laparoscopic Toupet fundoplication is an inadequate procedure for patients with severe reflux disease. J Gastrointest Surg 1999; 3: 583.
252. Gastal OL, Hagen JA, Peters JH. Short esophagus: analysis of predictors and clinical implications. Arch Surg 1999; 134: 633.
253. So JBY, Zeitel SM, Rattner DW. Outcomes of atypical symptoms attributed to gastroesophageal reflux treated by laparoscopic fundoplication. Surgery 1998; 124: 28.
254. Tran T, Spechler SJ, Richardson P, El-Serag HB. Fundoplication and the risk of esophageal cancer in gastroesophageal reflux disease: a Veteran's Affairs cohort study. Am J Gastroenterol 2005; 100: 1002.
255. Lundell L, Miettinen P, Myrvold HE, et al. Continued (5-year) follow-up of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg 2001; 192: 172.
256. Perdikis G, Hinder RA, Lund RJ, et al. Laparoscopic Nissen fundoplication: where do we stand? Surg Laparosc Endosc 1997; 7: 17.
257. Vakil N, Shaw M, Kriby R. Clinical effectiveness of laparoscopic fundoplication in a US community. Am J Med 2003; 114: 1.
258. Spechler SJ, Lee EL, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001; 285: 23331.
259. Lidums I, Lehmann A, Checklin H, et al. Control of transient lower esophageal sphincter relaxations and reflux by the GABAB agonist baclofen in normal subjects. Gastroenterology 2000; 118: 7.
260. Kahrilas PJ. Radiofrequency therapy for the lower esophageal sphincter for the treatment of GERD. Gastrointest Endosc 2003; 57: 723.
261. Fennerty MB. Endoscopic suturing for the treatment of GERD. Gastrointest Endosc 2003; 57: 390.
262. Edmundowicz SA. Injection therapy for the lower esophageal sphincter for the treatment of GERD. Gastrointest Endosc 2004; 59: 542.
263. Corley DA, Katz P, Wo JM, et al. Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized, sham-controlled trial. Gastroenterology 2003; 125: 668.
264. Deviere J, Costamanga G, Neuhas H, et al. Nonresorable copolymer implantation for gastroesophageal reflux disease: a randomized sham-controlled multicenter trial. Gastroenterology 2005; 128: 532.
265. Falk GW, Fennerty MB, Rothestein RI. AGA Institute technical review on the use of endoscopic therapy for gastroesophageal reflux disease. Gastroenterology 2006; 131: 1351.